cell-free DNA
Researchers confirmed prior data showing 100 percent accuracy for the test, but in a clinical-use population where they also observed growing adoption by physicians.
The firm recently published the results of a large cancer screening study in asymptomatic people and has launched another in symptomatic people.
Oncocyte Enters $29.1M Securities Purchase Agreement
The company expects the funds to be sufficient to complete development of its IVD diagnostic transplant assay program.
Grail Q3 Revenues Rise 39 Percent
Grail reported that strong sales of its blood-based Galleri cancer early detection test drove revenue growth in its first operating quarter as a public company.
The research team looked at cell-free DNA fragmentation profiles across the genome combined with measurements of two key biomarkers to detect ovarian cancer.
Oct 29, 2024
Sep 25, 2023